BioCentury
ARTICLE | Clinical News

CV Therapeutics completes CARISA Phase III

August 8, 2001 7:00 AM UTC

CVTX completed enrollment of more than 700 chronic angina patients in a 12-week, double-blind, placebo-controlled international Phase III trial of ranolazine. The CARISA (combination assessment of ran...